Nutex Health (NASDAQ:NUTX) Shares Up 15.3% Following Earnings Beat

Key Points

• Shares jumped 15.3% after quarterly results as EPS beat expectations ($6.52 vs. $3.99), although revenue missed at $216.49M versus $227.80M expected.
• Analyst views are mixed but tilted positive with an average rating of "Moderate Buy" and an average price target of $252.50 (two Buys, one Hold reported).
• Nutex Health has a market cap of about $958.6M and a P/E of 15.27, with strong liquidity (quick ratio 3.39, current ratio 3.41) and relatively low institutional ownership at 5.32%.

Nutex Health Inc. (NASDAQ:NUTX - Get Free Report)'s share price shot up 15.3% during trading on Friday following a better than expected earnings announcement. The stock traded as high as $140.74 and last traded at $137.3850. 79,310 shares traded hands during trading, a decline of 60% from the average session volume of 196,113 shares. The stock had previously closed at $119.20.

The company reported $6.52 EPS for the quarter, beating the consensus estimate of $3.99 by $2.53. Nutex Health had a return on equity of 17.67% and a net margin of 7.34%.The business had revenue of $216.49 million for the quarter, compared to analysts' expectations of $227.80 million.

Wall Street Analyst Weigh In

Several brokerages recently commented on NUTX. Weiss Ratings reiterated a "hold (c)" rating on shares of Nutex Health in a report on Friday, March 27th. Wall Street Zen cut Nutex Health from a "strong-buy" rating to a "hold" rating in a report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Nutex Health currently has an average rating of "Moderate Buy" and an average price target of $252.50.

Hedge Funds Weigh In On Nutex Health

Large investors have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new position in shares of Nutex Health in the 3rd quarter worth $30,000. Islay Capital Management LLC bought a new position in shares of Nutex Health in the 4th quarter worth $34,000. BNP Paribas Financial Markets lifted its holdings in shares of Nutex Health by 966.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company's stock worth $40,000 after purchasing an additional 290 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Nutex Health by 752.4% in the 4th quarter. Royal Bank of Canada now owns 358 shares of the company's stock worth $59,000 after purchasing an additional 316 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Nutex Health by 6,590.3% in the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company's stock worth $66,000 after purchasing an additional 2,043 shares in the last quarter. 5.32% of the stock is currently owned by institutional investors.

Nutex Health Trading Up 15.4%

The business has a fifty day moving average of $102.21 and a 200-day moving average of $126.29. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.39 and a current ratio of 3.41. The company has a market capitalization of $958.62 million, a P/E ratio of 15.27 and a beta of 0.10.

About Nutex Health

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.